iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Average Rating of “Hold” from Analysts

iTeos Therapeutics, Inc. (NASDAQ:ITOS) has received an average rating of “Hold” from the seven research firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $17.86.

A number of equities analysts have recently weighed in on ITOS shares. Leerink Partnrs downgraded shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 14th. HC Wainwright downgraded shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 14th. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. JPMorgan Chase & Co. downgraded shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $15.00 to $8.00 in a research note on Tuesday, May 13th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $9.00 price target (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th.

iTeos Therapeutics Stock Down 0.7%

Shares of NASDAQ:ITOS opened at $8.35 on Wednesday. iTeos Therapeutics has a 12-month low of $4.80 and a 12-month high of $18.30. The company has a market cap of $319.59 million, a P/E ratio of -2.65 and a beta of 1.39. The company’s fifty day moving average is $6.65 and its two-hundred day moving average is $7.40.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14. Equities research analysts anticipate that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Insiders Place Their Bets

In other iTeos Therapeutics news, major shareholder Ansbert Gadicke sold 1,031,931 shares of the company’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the sale, the insider now directly owns 3,452,797 shares in the company, valued at $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the company’s stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the sale, the insider now owns 2,108,594 shares of the company’s stock, valued at $16,995,267.64. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On iTeos Therapeutics

A number of hedge funds have recently bought and sold shares of ITOS. Point72 Asia Singapore Pte. Ltd. bought a new stake in iTeos Therapeutics during the fourth quarter valued at about $42,000. CWM LLC raised its position in iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company’s stock worth $51,000 after purchasing an additional 6,936 shares in the last quarter. Paloma Partners Management Co acquired a new stake in shares of iTeos Therapeutics during the first quarter worth approximately $65,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of iTeos Therapeutics during the first quarter worth approximately $67,000. Finally, Virtus ETF Advisers LLC increased its holdings in shares of iTeos Therapeutics by 58.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after buying an additional 3,293 shares in the last quarter. 97.16% of the stock is currently owned by institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.